Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases

Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD). 

Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases

SHARE

FacebookTwitterLinkedInYoutube
Event F.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator